Short answer
Zimmer Biomet (ZBH) filed its Q2 2026 10-Q quarterly report on Aug 5, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $2.2B (up 4.8% year over year) with net income of $198M.
Q2 2026 key financials · XBRL
- Revenue
- $2.2B
- +4.8% YoY · +4.3% QoQ
- Net income
- $198M
- +29.8% YoY · −16.7% QoQ
- Operating margin
- 15.0%
- EPS (diluted)
- $1.03
- +33.8% YoY · −15.6% QoQ
Source: XBRL data from the Zimmer Biomet (ZBH) Q2 2026 10-Q on SEC EDGAR. USD.
Zimmer Biomet Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No material risk-factor changes disclosed from the 2025 Form 10-K
- Debt refinancing risk from June 26, 2026 five-year and 364-day revolving credit agreements
- Liquidity exposure from $1.0 billion remaining under the $1.5 billion share-repurchase authorization
- Broad carried-forward business, financial-condition, and operating risks remain potentially material
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Zimmer Biomet quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.